Method of reducing tumor growth with IL-1beta neutralizing human monoclonal antibodies
The present invention is directed to antigen binding proteins and in particular to IL-1β antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.
1. A method of reducing tumor growth in a subject in need thereof, comprising administering to the subject an effective amount of an isolated monoclonal antibody, which specifically binds to IL-1β, or an antigen binding fragment thereof, wherein said antibody or fragment thereof comprises:
(i) Complementarity Determining Regions (CDRs) according to the Kabat numbering convention of a light chain comprising the amino acid sequence of SEQ ID NO: 17; and
(ii) CDRs according to the Kabat numbering convention of a heavy chain comprising the amino acid sequence of SEQ ID NO: 14.
2. The method of claim 1 , wherein the IL-1β is human, and wherein the antibody or fragment is fully human.
3. The method of claim 2 , wherein the antibody is of the subtype IgG1, IgG2, IgG3 or IgG4.
4. The method of claim 3 , wherein the antibody is of the subtype IgG4.
5. The method of claim 1 , wherein the antibody or fragment is in a composition, and wherein the composition further comprises a pharmaceutically acceptable carrier.
6. A method of reducing tumor growth in a subject in need thereof, comprising administering to the subject an effective amount of an isolated monoclonal antibody which specifically binds to IL-1β, or an antigen binding fragment thereof, wherein said antibody or fragment thereof comprises the following Complementarity Determining Regions (CDRs):
(i) a heavy chain variable region CDR H1 comprising the amino acid sequence of SEQ ID NO:26,
(ii) a heavy chain variable region CDR H2 comprising the amino acid sequence of SEQ ID NO:27,
(iii) a heavy chain variable region CDR H3 comprising the amino acid sequence of SEQ ID NO:28,
(iv) a light chain variable region CDR L1 comprising the amino acid sequence of SEQ ID NO:29,
(v) a light chain variable region CDR L2 comprising the amino acid sequence of SEQ ID NO:30, and
(vi) a light chain variable region CDR L3 comprising an amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID NO:11, SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:13.
7. The method of claim 6 , wherein the light chain variable region CDR L3 comprises the amino acid sequence of SEQ ID NO:12.
8. The method of claim 6 , wherein the light chain variable CDR3 comprises the amino acid sequence of SEQ ID NO:11.
9. The method of claim 6 , wherein the IL-1β is human, and wherein the antibody or fragment is fully human.
10. The method of claim 6 , wherein the antibody is of the subtype IgG1, IgG2, IgG3 or IgG4.
11. A method of reducing tumor growth in a subject in need thereof, comprising administering to the subject an effective amount of an isolated monoclonal antibody which specifically binds to IL-1β, or an antigen binding fragment thereof, wherein said antibody or fragment thereof comprises:
(i) a light chain sequence comprising the amino acid sequence of SEQ ID NO: 17; and
(ii) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 18.
12. The method of claim 11 , wherein the heavy chain sequence comprises the amino acid sequence of SEQ ID NO: 14.
13. The method of claim 11 , wherein the IL-1β is human, and wherein the antibody or fragment is fully human.
14. The method of claim 11 , wherein the antibody is of the subtype IgG1, IgG2, IgG3 or IgG4.